证券代码：300706 证券简称：阿石创 公告编号：2025-044 福建阿石创新材料股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏。 福建阿石创新材料股份有限公司（以下简称"公司"）近日接到公司控股股东、 实际控制人之一陈钦忠先生函告，获悉其所持有本公司的部分股份办理了解除质押 业务，具体事项如下： 一、本次股东股份解除质押基本情况 注：上述合计数占比差异均为四舍五入原因造成，下同。 | | 是否为控股 | 本次解 | 占其所直 | 占公司总 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | 除质押 | 接持有股 | 股本比例 | 质押 | 解除 | 质权人 | | 名称 | 大股东及其 | 数（万 | 份比例 | （%） | 起始日 | 质押日 | | | | 一致行动人 | 股） | （%） | | | | | | 陈钦忠 | 是 | 150 | 3.10 | 0.98 | 2023年9月13日 | ...

Market Performance - The superconducting concept index rose by 0.68%, ranking fourth among concept sectors, with 10 stocks increasing in value [1] - Notable gainers included Yongding Co., Ltd. and Wolong Nuclear Materials, which hit the daily limit, while Astone Creation, Jingda Co., and Baiyin Nonferrous Metals also saw significant increases of 8.46%, 5.34%, and 2.93% respectively [1] - The biggest decliners were Ningbo Yunsheng, Wandong Medical, and Dongfang Tantalum, which fell by 3.26%, 2.86%, and 2.86% respectively [1] Capital Flow - The superconducting concept sector experienced a net inflow of 1.322 billion yuan, with 10 stocks receiving net inflows, and 5 stocks attracting over 50 million yuan each [1] - Wolong Nuclear Materials led the net inflow with 1.148 billion yuan, followed by Yongding Co. with 444 million yuan, Baiyin Nonferrous Metals with 129 million yuan, and Jingda Co. with 96 million yuan [1] - The net inflow ratios for Yongding Co., Wolong Nuclear Materials, and Baiyin Nonferrous Metals were 17.12%, 14.27%, and 10.39% respectively [2] Stock Performance - The top performers in the superconducting concept included Wolong Nuclear Materials and Yongding Co., both achieving a daily increase of 10% [2] - Other notable stocks included Astone Creation with an 8.46% increase and Jingda Co. with a 5.34% increase [2] - Conversely, stocks like Ningbo Yunsheng and Wandong Medical saw declines of 3.26% and 2.86% respectively [3]

Core Viewpoint - The titanium target material industry is experiencing significant growth due to its critical applications in high-tech fields such as semiconductors, medical devices, and aerospace, with a projected market size of 2.802 billion yuan in China by 2024, reflecting an 8.35% year-on-year increase [1][8]. Industry Overview - Titanium target materials are made from high-purity titanium or titanium alloys, exhibiting excellent corrosion resistance, high strength, low density, and good biocompatibility, primarily used in semiconductor manufacturing, flat panel displays, decorative coatings, and vacuum equipment [4][6]. - The industry is supported by favorable policies, including subsidies and tax incentives, as outlined in the "14th Five-Year" new materials industry development plan, which identifies sputtering target materials as a key area for breakthroughs [1][8]. Market Size and Growth - The market size of China's titanium target material industry is expected to reach 2.802 billion yuan in 2024, with an increase of 8.35% compared to the previous year [1][9]. - The global semiconductor industry is projected to recover in 2024, with sales reaching $627.6 billion, a 19.1% increase year-on-year, driving demand for titanium targets as semiconductor nodes advance to 3nm and below [7][8]. Industry Chain - The titanium target material industry chain consists of upstream raw material and equipment suppliers, midstream manufacturers, and downstream application sectors, including semiconductors, medical devices, aerospace, and automotive manufacturing [7]. - China's titanium ore production is expected to decline by 6.3% to 3.044 million tons in 2024, but China remains the largest producer globally, accounting for 35.1% of total production [7]. Competitive Landscape - The industry is characterized by intense competition, with companies like Jiangfeng Electronics leading the first tier, followed by Longhua Technology, Ashi Innovation, and others in the second tier [10]. - Jiangfeng Electronics specializes in ultra-high-purity metal sputtering targets and has seen a 23.91% year-on-year increase in revenue, reaching 1.325 billion yuan in the first half of 2025 [11]. Development Trends - Future trends in the titanium target material industry include the adoption of advanced manufacturing processes such as powder metallurgy and 3D printing to enhance production efficiency and product quality [12]. - There is a growing emphasis on sustainability, with a focus on energy conservation and recycling in production processes, alongside expanding applications in emerging fields like new energy storage and biomedical materials [12].

Group 1 - The rare earth permanent magnet sector in the A-share market has seen a significant decline, with companies like China Rare Earth and Shenghe Resources approaching their daily limit down [1] - Northern Rare Earth has dropped over 8%, while Tongcheng New Materials has decreased by more than 7% [1] - Other companies such as Aishi Chuang, Xiamen Tungsten, Guangsheng Nonferrous, and Youyan New Materials have all experienced declines exceeding 6% [1]

Group 1 - The core viewpoint of the news is that Astone Innovation has shown significant stock performance with a year-to-date increase of 74.14% and a recent market capitalization of 6.417 billion yuan [2] - As of September 3, Astone Innovation's stock price reached 41.88 yuan per share, with a trading volume of 1.49 billion yuan and a turnover rate of 3.19% [1] - The company has experienced a net inflow of main funds amounting to 4.9509 million yuan, with large orders contributing to a total buy of 29.1164 million yuan and a sell of 30.0610 million yuan [1] Group 2 - Astone Innovation's main business involves the research, production, and sales of various PVD coating materials, with revenue composition as follows: sputtering targets 42.65%, evaporation materials 31.64%, alloy and metal materials 22.47%, and others 3.24% [2] - The company has been listed on the Longhu list five times this year, with the most recent net purchase on August 8 amounting to 60.1307 million yuan [2] - As of August 20, the number of shareholders for Astone Innovation increased to 48,600, with an average of 2,336 circulating shares per person [2] Group 3 - Since its A-share listing, Astone Innovation has distributed a total of 21.833 million yuan in dividends, with 6.1141 million yuan distributed in the last three years [3]

Core Viewpoint - The recent financial report of Aishi Chuang (300706) indicates a significant increase in revenue but a drastic decline in profit, highlighting challenges in maintaining profitability despite revenue growth [1] Financial Performance - As of the end of the reporting period, the company's total revenue reached 673 million yuan, a year-on-year increase of 15.11%, while the net profit attributable to shareholders was -29.5 million yuan, a year-on-year decrease of 693.98% [1] - In Q2, total revenue was 372 million yuan, up 17.75% year-on-year, but the net profit attributable to shareholders was -25.8 million yuan, down 415.61% year-on-year [1] - Key financial metrics include a gross margin of 3.91%, down 55.74% year-on-year, and a net margin of -4.55%, down 517.55% year-on-year [1] Cost Structure and Expenses - Total selling, administrative, and financial expenses amounted to 41.7 million yuan, accounting for 6.2% of revenue, an increase of 3.53% year-on-year [1] - The company's cash flow situation is concerning, with operating cash flow per share at -0.0 yuan, a decrease of 102.43% year-on-year [1] Business Model and Investment Returns - The company's business model relies heavily on capital expenditures, which raises concerns about the efficiency and necessity of these investments [3] - Historical data shows a median Return on Invested Capital (ROIC) of 5.12%, with the worst year being 2024 at -0.5%, indicating poor investment returns [3] Product and Market Position - The company is a leading supplier in the flat panel display sector, particularly in target materials like aluminum and molybdenum, with molybdenum targets holding the largest global market share [3] - Recent pressures on gross margins are attributed to new production lines and rising raw material costs, especially for precious metals [3][4] Production Capacity and Efficiency - The utilization rate of the company's target material production lines has averaged around 80%, but the front-end equipment utilization varies due to different product process requirements [6] - The overall improvement in gross margins is expected to come from new product development and changes in product supply structure, although rising raw material costs may continue to exert pressure [7] Raw Material Price Management - The company employs hedging strategies to manage price volatility for certain bulk materials, while fluctuations in precious metal prices require careful trend analysis and collaboration with upstream suppliers [8]

Core Viewpoint - The company, Ashi Chuang, announced its application for a loan of 30 million RMB from the Fuzhou Changle Branch of Agricultural Bank of China, with its wholly-owned subsidiary providing a guarantee for the loan [1] Group 1 - The total amount of guarantees provided by the company, including the new loan guarantee, is 73 million RMB, which accounts for 10.07% of the company's most recent audited net assets [1]

一、担保情况概述 为满足福建阿石创新材料股份有限公司（下称"公司"）日常经营需要，公司 向中国农业银行股份有限公司福州长乐支行（下称"农业银行"）申请贷款人民币 3,000 万元，公司全资子公司三明顶创恒隆材料有限责任公司（下称"三明顶创"） 为上述贷款提供最高额连带责任保证担保。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《公司章程》等相关规定，上述担保事项已经三明顶创股东决定通过程序， 无需提交公司董事会及股东大会审议。 上述担保事项不属于关联交易，也不存在反担保情形。 二、被担保人情况 证券代码：300706 证券简称：阿石创 公告编号：2025-043 福建阿石创新材料股份有限公司 关于公司担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏。 1、公司名称：福建阿石创新材料股份有限公司 2、注册资本：15,322.0499 万元 3、法定代表人：陈钦忠 4、成立日期：2002 年 10 月 29 日 5、注册地址：福州市长乐区漳港街道漳湖路 66 号 6、经营范围：金属、稀有金属、稀土、贵金属及其合金制成的 ...

Core Viewpoint - The company Astone Technology (300706.SZ) reported a significant shift from profit to loss in its half-year performance for 2025, indicating potential challenges in its financial health [1]. Financial Performance - The company's operating revenue reached 673 million yuan, reflecting a year-on-year growth of 15.11% [1]. - The net loss attributable to shareholders amounted to 29.50 million yuan [1]. - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 32.42 million yuan [1]. - The basic loss per share was reported at 0.19 yuan [1].

Market Performance - The pharmaceutical sector experienced a decline of -2.73% on August 27, 2025, underperforming the CSI 300 index by 1.24 percentage points, ranking 26th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (-1.37%), medical research outsourcing (-1.98%), and blood products (-2.06%) performed relatively better, while in vitro diagnostics (-3.98%), vaccines (-3.45%), and hospitals (-3.12%) lagged behind [1] - Top three gainers included Nanjing New Pharmaceutical (+20.00%), Ailis (+17.00%), and Aomei Medical (+10.04%), while the largest decliners were Yuekang Pharmaceutical (-16.82%), Rejing Bio (-10.47%), and Guangshengtang (-10.32%) [1] Industry News - Gilead announced that the European Commission has approved its HIV-1 capsid inhibitor Yeytuo (Lenacapavir) for market release as a pre-exposure prophylaxis (PrEP) therapy, aimed at reducing the risk of HIV-1 infection in high-risk adults and adolescents (weighing at least 35 kg) [2] - Lenacapavir is a "first-in-class" long-acting HIV capsid inhibitor that interferes with the assembly and disassembly of the HIV capsid protein, demonstrating a 100% prevention rate of HIV infection in a study with 2,134 participants receiving biannual subcutaneous injections, outperforming the daily oral Truvada treatment group [2] Company News - Xingqi Eye Pharmaceutical (300573) reported a revenue of 1.163 billion yuan for the first half of 2025, a year-on-year increase of 30.38%, with a net profit attributable to shareholders of 335 million yuan, up 97.75% [3] - Nossger (301333) achieved a revenue of 380 million yuan in the first half of 2025, a slight increase of 0.18%, with a net profit of 61 million yuan, growing by 4.45% [3] - Mindray Medical (300706) reported a revenue of 16.743 billion yuan for the first half of 2025, a decline of 18.45%, with a net profit of 5.069 billion yuan, down 32.96% [3] - Zhongsheng Pharmaceutical (002317) announced that its subsidiary Zhongsheng Ruichuang has completed the first participant enrollment and dosing for two Phase III clinical trials (SHINING-2 and SHINING-3) of its innovative polypeptide drug RAY1225 injection [3]